Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment

Gut

Volumn 63, Issue 3, 2014, Pages 494-505

  Schwaiger, Theresa ^a   Van Den Brandt, Cindy ^a   Fitzner, Brit ^b   Zaatreh, Sarah ^b   Kraatz, Franziska ^a   Dummer, Annegret ^a   Nizze, Horst ^c   Evert, Matthias ^a   Bröker, Barbara M ^a   Brunner Weinzierl, Monika C ^d   Wartmann, Thomas ^d   Salem, Tareq ^c   Lerch, Markus M ^a   Jaster, Robert ^b   Mayerle, Julia ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KEYWORDS: MRL/MP MICE, TREG, CTLA-4, TEFF, RAPAMYCIN, CYCLOSPORINE A, AZATHIOPRINE;

ANIMALS; AUTOIMMUNE DISEASES; AZATHIOPRINE; BIOLOGICAL MARKERS; CELL PROLIFERATION; CTLA-4 ANTIGEN; CYCLOSPORINE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; PANCREAS; PANCREATITIS, CHRONIC; POLY I-C; RANDOM ALLOCATION; SIROLIMUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84893779107     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303635     Document Type: Article

References (64)

1. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013;62:1607-15.
2. Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas 2011;40:809-14.
3. Lerch MM, Mayerle J. The benefits of diagnostic ERCP in autoimmune pancreatitis. Gut 2011;60:565-6.
4. Pickartz T, Mayerle J, Lerch MM. Autoimmune pancreatitis. Nature Clin Pract Gastroenterol Hepatol 2007;4:314-23. (Pubitemid 47393757)
5. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011;40:352-8.
6. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012;22:1-14.
7. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012;22:21-30.
8. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58:1504-7.
9. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009;7:1089-96.
10. Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch 2004;445:552-63. (Pubitemid 40104530)
11. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010;139:140-8; quiz e12-3.
12. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009;361:2135-42.
13. Naitoh I, Nakazawa T, Ohara H, et al. Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. Intern Med 2009;48:2003-7.
14. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62:1755-62.
15. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008;6:364-6. (Pubitemid 351318380)
16. Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009;104:2295-306.
17. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterol 2008;134:706-15. (Pubitemid 351312724)
18. Okazaki K, Uchida K, Miyoshi H, et al. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allergy Immunol 2011;41:126-38.
19. Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 2000;118:573-81. (Pubitemid 30140856)
20. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539-51.
21. Knieke K, Hoff H, Maszyna F, et al. CD152 (CTLA-4) determines CD4T cell migration in vitro and in vivo. PLoS ONE 2009;4:e5702.
22. Knieke K, Lingel H, Chamaon K, et al. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. PLoS ONE 2012;7:e31391.
23. Kolar P, Hoff H, Maschmeyer P, et al. CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells. Clin Exp Rheumatol 2011;29:254-60.
24. Kolar P, Knieke K, Hegel JK, et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 2009;60:123-32.
25. Pandiyan P, Gartner D, Soezeri O, et al. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med 2004;199:831-42. (Pubitemid 38375203)
26. Rudolph M, Hebel K, Miyamura Y, et al. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo. J Immunol 2011;186:5580-9.
27. Chang MC, Chang YT, Tien YW, et al. T-cell regulatory gene CTLA-4 polymorphism/ haplotype association with autoimmune pancreatitis. Clin Chem 2007;53:1700-5.
28. Umemura T, Ota M, Hamano H, et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 2008;103:588-94. (Pubitemid 351406007)
29. Asghari F, Fitzner B, Holzhuter SA, et al. Identification of quantitative trait loci for murine autoimmune pancreatitis. J Med Genet 2011;48:557-62.
30. Fitzner B, Holzhueter SA, Ibrahim S, et al. Interferon-gamma treatment accelerates and aggravates autoimmune pancreatitis in the MRL/Mp-mouse. Pancreatology 2009;9:233-9.
31. Sorg H, Lorch B, Jaster R, et al. Early rise in inflammation and microcirculatory disorder determine the development of autoimmune pancreatitis in the MRL/ Mp-mouse. Ame J Physiol Gastrointest Liver Physiol 2008;295:G1274-80.
32. Kanno H, Nose M, Itoh J, et al. Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism. Clin Exp Immunol 1992;89:68-73.
33. Qu WM, Miyazaki T, Terada M, et al. A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid. Clin Exp Immunol 2002;129:27-34.
34. Asada M, Nishio A, Akamatsu T, et al. Analysis of humoral immune response in experimental autoimmune pancreatitis in mice. Pancreas 2010;39:224-31.
35. Asada M, Nishio A, Uchida K, et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 2006;33:20-6. (Pubitemid 43995335)
36. Nishio A, Asada M, Uchida K, et al. The role of innate immunity in the pathogenesis of experimental autoimmune pancreatitis in mice. Pancreas 2011;40:95-102.
37. Tivol EA, Boyd SD, McKeon S, et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997;158:5091-4. (Pubitemid 127681209)
38. Berenbaum MC. Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol 1971;8:1-8.
39. Jonsson CA, Erlandsson M, Svensson L, et al. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol 1999;197:136-44. (Pubitemid 30000734)
40. Joseph A, Munroe K, Housman M, et al. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008;152:138-46. (Pubitemid 351347554)
41. Lange F, Bajtner E, Rintisch C, et al. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Annals of the rheumatic diseases 2005;64:599-605. (Pubitemid 40469091)
42. Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, et al. Prevention ofmurine lupus disease in (NZBxNZW)F1 mice by rapamycin treatment. Lupus 2007; 16:775-81. (Pubitemid 350069789)
43. Takae Y, Nishikawa T, Amagai M. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp Dermatol 2009;18:252-60.
44. Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 2006;108:1965-71. (Pubitemid 44395007)
45. Zenker M, Mayerle J, Lerch MM, et al. Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation ( Johanson-Blizzard syndrome). Nat Genet 2005;37:1345-50. (Pubitemid 41722190)
46. Sendler M, Dummer A, Weiss FU, et al. Tumour necrosis factor alpha secretion induces protease activation and acinar cell necrosis in acute experimental pancreatitis in mice. Gut 2013;62:430-9.
47. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7. (Pubitemid 24291979)
48. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007;45:1538-46. (Pubitemid 46918338)
49. Uchida K, Okazaki K, Nishi T, et al. Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin. Lab Invest 2002;82:411-24. (Pubitemid 34311114)
50. Lohr JM, Faissner R, Koczan D, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010;105:2060-71.
51. Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naive and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas 2008;36:133-40.
52. Murray LJ, Lee R, Martens C. In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur J Immunol 1990;20:163-70. (Pubitemid 20087043)
53. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol/ Hematol 2005;56:23-46. (Pubitemid 41278644)
54. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998;27:1536-43.
55. Hashimoto Y, Matsuoka N, Kawakami A, et al. Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis. Clin Exp Immunol 2001;125:19-24. (Pubitemid 32703361)
56. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324-37.
57. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006;55:40-9. (Pubitemid 43343297)
58. Sakaguchi Y, Inaba M, Tsuda M, et al. The Wistar Bonn Kobori rat, a unique animal model for autoimmune pancreatitis with extrapancreatic exocrinopathy. Clin Exp Immunol 2008;152:1-12. (Pubitemid 351347541)
59. Yamada T, Hashimoto T, Sogawa M, et al. Role of T cells in development of chronic pancreatitis in male Wistar Bonn/Kobori rats: effects of tacrolimus. Am J Physiol Gastrointest Liver Physiol 2001;281:G1397-404.
60. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-92.
61. Kloppel G, Detlefsen S, Chari ST, et al. Autoimmune pancreatitis: the clinicopathological characteristics of the subtype with granulocytic epithelial lesions. J Gastroenterol 2010;45:787-93.
62. Jaster R, Emmrich J. Molecular characteristics of autoimmune pancreatitis. Cur Pharm Des 2006;12:3781-6. (Pubitemid 44560711)
63. Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, et al. Extraintestinal manifestations of autoimmune pancreatitis. Dig Dis 2012;30:220-3.
64. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771-6.